Transformative Shift: Qualigen Therapeutics Becomes AIxCrypto
Dubai, UAE / Beijing, China -- Qualigen Therapeutics Inc. (NASDAQ: QLGN), a cutting-edge technology company, is preparing for a significant transformation. Following a stockholder meeting, the company will officially rebrand itself as AIxCrypto. This move signals an exciting evolution as it embraces Web3 and cryptocurrency initiatives to better serve its growing user base.
Strategic Roadmap for AIxCrypto
With the upcoming rebrand to AIxCrypto, the company is laying out a bold strategic vision that underscores its commitment to innovation within the crypto asset space. Before the end of November, AIxCrypto will introduce the public beta of its BesTrade DeAI Agent, showcasing the company's dedication to integrating advanced technological solutions into the trading arena.
Major Goals for Future Success
The newly rebranded AIxCrypto has set ambitious objectives to be achieved by the end of 2025. Here are the three core goals that will guide the organization in this transformative journey:
1. Expand the C10 Treasury
One of the primary goals is to significantly increase the C10 Treasury to $50 million in Assets Under Management (AUM). This treasury will play a pivotal role as a core reserve asset within the Web3 ecosystem, creating critical value through innovative products like the C10 Index.
2. Accelerate Growth of BesTrade DeAI Agent
AIxCrypto plans to globally expand its user base for the BesTrade DeAI Agent, its flagship product. Designed as a Meta Exchange, this tool enhances transaction pathways and optimizes returns for users. Following its beta launch, a concentrated marketing effort will be initiated to position the platform among the elite AI trading services available.
3. Launch Crypto Ecosystem Tokens
Additionally, the company aims to introduce various crypto ecosystem tokens across leading exchanges. This initiative will be supplemented by the potential launch of a stablecoin and dual-bridge products, enabling AIxCrypto to establish a sustainable, on-chain value growth system that robustly supports the ecosystem's development.
About Qualigen Therapeutics, Inc.
Qualigen Therapeutics Inc. (NASDAQ: QLGN) focuses on developing groundbreaking therapeutic solutions in biotechnology. The company originates from the principles of innovation and science-driven growth, now expanding its reach into the Web3 sector. By harnessing the synergy between pharmaceuticals and digital assets, Qualigen is set to strategically innovate and attract investment, thereby enhancing its position in both biotechnology and crypto markets.
Frequently Asked Questions
What prompted the rebranding of Qualigen to AIxCrypto?
The rebranding reflects Qualigen’s strategic shift towards Web3 and crypto asset initiatives, aiming to innovate its offerings in the digital space.
What are the major goals for AIxCrypto by 2025?
AIxCrypto's goals include expanding the C10 Treasury, accelerating the growth of the BesTrade DeAI Agent, and launching crypto ecosystem tokens on major exchanges.
How does the BesTrade DeAI Agent function?
The BesTrade DeAI Agent serves as a Meta Exchange, optimizing transaction pathways to effectively enhance user experience and returns.
What is the significance of the C10 Treasury?
The C10 Treasury is designed to act as a reserve asset for the Web3 ecosystem, providing foundational support and stability for AIxCrypto’s initiatives.
Who can I contact for more information about AIxCrypto?
Contact the Investor Relations Department of Qualigen Therapeutics at 5857 Owens Avenue, Suite 300, Carlsbad, CA 92008, or call +1 (760) 452-8111 for inquiries.
